Traction for the respiratory portfolio, including commercialization hopes for one yet undisclosed “big product” in Europe, and the anticipated debut of a partnered COVID-19 nasal spray in India and other markets, point to an action-packed 2022 for Glenmark Pharmaceuticals Limited amid pandemic uncertainties.
Glenmark’s Ryaltris (olopatadine/mometasone furoate nasal spray) appears to have made significant strides in recent launch markets globally and the Indian...





![Spotlight On RDCs, AOCs As Leading Novel Bioconjugates[Updated]](https://web.insights.norstella-labs.com/resizer/v2/3M7ZAWZOBNK7NG4A4WDOIFG6DU.jpg?smart=true&auth=392a1fdb3cfacb29445720c412410e598dbcc5f90f14857652cd498bd0faa0fb&width=400&height=225)
